India, Oct. 15 -- Eikon Therapeutics Inc. (EIKN), a late clinical-stage biopharmaceutical company, on Thursday reported the submission of an investigational new drug (IND) application for EIK1006 in treating prostate cancer. Prostate cancer is a malignancy of the prostate gland in males. With over 300,000 new cases diagnosed annually in the U.S. alone, early treatment is often key to survival. The severity of the disease is measured using Gleason scores, which grade the extent of abnormality in tumor cells from a biopsy. EIK1006 is a novel androgen receptor (AR) antagonist that targets hormone-producing cells in the prostate gland. By preventing the excess growth of these cells before a malignancy advances, the drug differs from the current...